Cost-effectiveness of alternative first- and second-line treatments for benign prostatic hyperplasia in Singapore.
Junxing ChayJoshua Yi Min TungRebecca Jade SuEdwin Jonathan AslimCallix WongGeorgia SwanWei Jin ChuaHenry Sun Sien HoEric Andrew FinkelsteinPublished in: Journal of medical economics (2023)
Based on the common willingness-to-pay threshold of SGD 50,000/QALY, this study demonstrates the cost-effectiveness of WVTT over MM as first-line treatment for patients with moderate or severe BPH, suggesting it represents good value for money and should be considered for subsidy. PUL is not cost-effective as first- nor second-line treatment. For patients with severe BPH, TURP as first-line is also cost-effective.